Fluorine »
PDB 6ugr-6v2u »
6ut0 »
Fluorine in PDB 6ut0: Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer
Protein crystallography data
The structure of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer, PDB code: 6ut0
was solved by
G.P.Vigers,
D.J.Smith,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
| Resolution Low / High (Å) | 28.32 / 1.94 |
| Space group | P 1 21 1 |
| Cell size a, b, c (Å), α, β, γ (°) | 74.918, 61.800, 76.050, 90.00, 111.37, 90.00 |
| R / Rfree (%) | 17.5 / 22.2 |
Other elements in 6ut0:
The structure of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer also contains other interesting chemical elements:
| Magnesium | (Mg) | 4 atoms |
| Chlorine | (Cl) | 4 atoms |
Fluorine Binding Sites:
The binding sites of Fluorine atom in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer
(pdb code 6ut0). This binding sites where shown within
5.0 Angstroms radius around Fluorine atom.
In total 4 binding sites of Fluorine where determined in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer, PDB code: 6ut0:
Jump to Fluorine binding site number: 1; 2; 3; 4;
In total 4 binding sites of Fluorine where determined in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer, PDB code: 6ut0:
Jump to Fluorine binding site number: 1; 2; 3; 4;
Fluorine binding site 1 out of 4 in 6ut0
Go back to
Fluorine Binding Sites List in 6ut0
Fluorine binding site 1 out
of 4 in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer
Mono view
Stereo pair view
Mono view
Stereo pair view
A full contact list of Fluorine with other atoms in the F binding
site number 1 of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer within 5.0Å range:
|
Fluorine binding site 2 out of 4 in 6ut0
Go back to
Fluorine Binding Sites List in 6ut0
Fluorine binding site 2 out
of 4 in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer
Mono view
Stereo pair view
Mono view
Stereo pair view
A full contact list of Fluorine with other atoms in the F binding
site number 2 of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer within 5.0Å range:
|
Fluorine binding site 3 out of 4 in 6ut0
Go back to
Fluorine Binding Sites List in 6ut0
Fluorine binding site 3 out
of 4 in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer
Mono view
Stereo pair view
Mono view
Stereo pair view
A full contact list of Fluorine with other atoms in the F binding
site number 3 of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer within 5.0Å range:
|
Fluorine binding site 4 out of 4 in 6ut0
Go back to
Fluorine Binding Sites List in 6ut0
Fluorine binding site 4 out
of 4 in the Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer
Mono view
Stereo pair view
Mono view
Stereo pair view
A full contact list of Fluorine with other atoms in the F binding
site number 4 of Identification of the Clinical Development Candidate MRTX849, A Covalent KRASG12C Inhibitor For the Treatment of Cancer within 5.0Å range:
|
Reference:
J.B.Fell,
J.P.Fischer,
B.R.Baer,
J.F.Blake,
K.Bouhana,
D.M.Briere,
K.D.Brown,
L.E.Burgess,
A.C.Burns,
M.R.Burkard,
H.Chiang,
M.J.Chicarelli,
A.W.Cook,
J.J.Gaudino,
J.Hallin,
L.Hanson,
D.P.Hartley,
E.J.Hicken,
G.P.Hingorani,
R.J.Hinklin,
M.J.Mejia,
P.Olson,
J.N.Otten,
S.P.Rhodes,
M.E.Rodriguez,
P.Savechenkov,
D.J.Smith,
N.Sudhakar,
F.X.Sullivan,
T.P.Tang,
G.P.Vigers,
L.Wollenberg,
J.G.Christensen,
M.A.Marx.
Identification of the Clinical Development CANDIDATEMRTX849, A Covalent KRASG12CINHIBITOR For the Treatment of Cancer. J.Med.Chem. 2020.
ISSN: ISSN 0022-2623
PubMed: 32250617
DOI: 10.1021/ACS.JMEDCHEM.9B02052
Page generated: Fri Aug 2 02:36:29 2024
ISSN: ISSN 0022-2623
PubMed: 32250617
DOI: 10.1021/ACS.JMEDCHEM.9B02052
Last articles
Zn in 2YRCZn in 2YQP
Zn in 2YR2
Zn in 2YQL
Zn in 2YPT
Zn in 2YPA
Zn in 2YPU
Zn in 2YNW
Zn in 2YNT
Zn in 2YNV
